Fintel reports that on January 10, 2025, Roth MKM initiated coverage of Verona Pharma plc - Depositary Receipt () ...

Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Verona Pharma plc ( NASDAQ:VRNA ) is possibly approaching a major achievement in its business, so we would like ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Verona Pharma (NASDAQ:VRNA – Get Free Report) had its price target raised by investment analysts at Wells Fargo & Company ...

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

In recent trading, shares of Verona Pharma plc (Adderbury) (Symbol: VRNA) have crossed above the average analyst 12-month target price of $47.28, changing hands for $48.20/share. When a stock ...

Sanctuary Advisors LLC acquired a new stake in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) in the third quarter, ...